Royal Bank of Canada
OASM

Royal Bank of Canada’s Oasmia Pharmaceutical AB OASM Stock Holding History

Royal Bank of Canada’s Portfolio OASM Stock Details OASM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-175
Closed – – 7418
2019
Q1 		$0 Buy
+175
New +$480 ﹤0.01% 7310

Other funds holding OASM

CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return

Royal Bank of Canada's OASM Position: Q2 2019 in Review

Royal Bank of Canada sold out of Oasmia Pharmaceutical AB (OASM) in Q2 2019, closing a stake of 175 shares.

Royal Bank of Canada first reported a position in OASM in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 4 funds tracked by Wall St. Rank hold OASM as of Q2 2019.

  • Royal Bank of Canada reported no remaining Oasmia Pharmaceutical AB position as of Q2 2019 after selling out during the quarter.
  • Royal Bank of Canada sold 175 Oasmia Pharmaceutical AB shares in Q2 2019.
  • Royal Bank of Canada first reported a position in Oasmia Pharmaceutical AB in Q1 2019 and held it in 1 quarter.
  • Royal Bank of Canada's Oasmia Pharmaceutical AB position peaked at $0 in Q1 2019.
  • 4 funds tracked by Wall St. Rank held Oasmia Pharmaceutical AB as of Q2 2019.

Based on Royal Bank of Canada's 13F filing for Q2 2019, filed 14 Aug 2019.